Media Reactions to Abridge’s Next Chapter: Series E

This week, Abridge announced a $300 million Series E funding round, led by a16z and joined by Khosla Ventures and other leading investors. How did we get here and where are we going? The highlights from media coverage tell the story: 

“Health systems and medical practices are increasingly turning to ambient AI technology to help with burdensome medical documentation. This shift is propelling Abridge's rapid growth.”

(Generative AI company Abridge scores $300M series E backed by a16z and Khosla Ventures – Fierce Healthcare, 6/24)

“The company reorganized its website on the heels of its Series E news, adjusting ‘product’ to ‘platform’—a change that is rooted in more than linguistics. Dr. Rao said it is focused on the layers of value that unlock when clinical conversations become more than notes and start working like infrastructure.”

(With a $5.3B valuation, Abridge sends a message: Note-taking was just the start – Becker’s Hospital Review, 6/25)

“Among other product developments, the funds will help Abridge embed checking and validating of billing codes during patient conversations.”

(Abridge valued at $5.3B as it moves to codify billing – Axios, 6/24)

“Matt Kull, chief information and digital strategy officer of Inova Health System, said the Northern Virginia-based health system is expanding the use of Abridge’s product from its 2,000 doctors to include its 6,000 nurses.”

(Abridge, Whose AI App Takes Notes for Doctors, Valued at $5.3 Billion at Funding – WSJ, 6/24)

“The 7-year-old Abridge is widely considered to be the leader in the increasingly crowded AI-powered medical scribe market.”

(In just 4 months, AI medical scribe Abridge doubles valuation to $5.3B – TechCrunch, 6/24)